Sandoz Opens Two European Sites, In Biosimilars And Antibiotics
Announcement Comes As Company Raises €2.0bn In Debt Following Spin
Newly separated Sandoz has provided a trio of updates, foremost for its manufacturing and research ambitions for both biosimilars and antibiotics.
You may also be interested in...
Reporting its first results as a standalone company, Sandoz has delivered double-digit growth in biosimilars for the first nine months of 2023, helping to lift the overall business as generics also enjoyed a more modest increase.
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.